Connect with us

Company News

AstraZeneca Pharma India Ltd Receives Permission For Calquence From DCGI

AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (Marketing Authorization – Additional Indication) from the Drugs Controller General of India (DCGI) for Acalabrutinib 100mg capsules (Calquence®).

The receipt of this Import and Market permission paves way for the launch of Acalabrutinib 100mg capsules (Calquence®) in India, subject to the receipt of related statutory approvals and licenses.

Acalabrutinib 100mg capsules is indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.2256.15 as compared to the previous close of Rs. 2462.65. The total number of shares traded during the day was 2515 in over 1005 trades.

The stock hit an intraday high of Rs. 2400 and intraday low of 2060.4. The net turnover during the day was Rs. 5596485.-Equity Bulls

Copyright © 2024 Medical Buyer

error: Content is protected !!